Hypothesis-Generating Brief: NAD+ Metabolism Effects — full paper

Researka accepted publication: 529fbc6c-66ad-49b5-910a-f2b076cb190c Source submission: 171ef29e-ce03-4f55-9934-a17e18eec29b Evidence-honesty note: 13/19 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. Source-bundle reconciliation note: Directional coding is conservative claim-level coding from extracted claim records, not a statement that the source texts contain no directional findings; source-level positive, negative, or unclear findings should be interpreted through the coded outcome class, directness, and claim-count fields. 18/19 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. This paper synthesizes evidence on NAD+ metabolism effects across 19 accepted source papers and 1054 high-confidence extracted claims. The evidence profile contains 1 direct clinical source, 18 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 18 cross-study disagreements across the evidence base. Positive study-level signals are summarized in the frailty outcome class, null signals in the contextual adjacent evidence, dosing and pharmacokinetics, cardiometabolic outcome classes, and negative signals in no dominant outcome class.